10-Q: IMAC Holdings Faces Severe Financial Headwinds Amid Strategic Shift to Precision Medicine

IMAC Holdings, Inc. reported a significant increase in net loss and cash burn for the first quarter of 2025, raising substantial doubt about its ability to continue as a going concern, despite a strategic pivot to precision cancer treatment.

Summary

• IMAC Holdings, Inc. reported a net loss of $2,199,868 for the three months ended March 31, 2025, a substantial increase from a net loss of $407,219 in the same period of 2024.
• The net loss available to common stockholders worsened significantly to $3,414,205 in Q1 2025, compared to $616,584 in Q1 2024, primarily due to higher preferred dividends of $1,214,337.
• Revenues from continuing operations, focused on precision medicine in cancer treatment, were minimal at $1,500 for Q1 2025, up from $0 in Q1 2024, but were offset by $103,187 in cost of revenues, resulting in a gross loss of $101,687.
• Operating expenses surged to $2,087,214 in Q1 2025 from $408,630 in Q1 2024, driven by increased employee expenses ($802,041), professional fees ($1,063,205), and legal fees ($0.5 million).
• Cash decreased significantly to $30,880 as of March 31, 2025, from $504,189 at December 31, 2024.
• The company's working capital deficit increased to $(8.5) million as of March 31, 2025, from $(7.3) million at December 31, 2024, with total current liabilities reaching $8.8 million.
• Net cash used in operating activities increased to $1,033,309 in Q1 2025, compared to $202,252 in Q1 2024.
• Shareholders approved an increase in authorized common stock to 120,000,000 shares from 60,000,000 shares on March 26, 2025.
• The company issued promissory notes totaling approximately $0.7 million in principal, yielding $0.5 million in cash proceeds during Q1 2025, and subsequently issued an additional $1.7 million in principal notes for $1.2 million cash after the quarter end.
• Material weaknesses in internal control over financial reporting were identified, including insufficient accounting resources and lack of segregation of duties.

Sentiment

Score: 2

Explanation: The company is in severe financial distress, evidenced by a significant increase in net losses, high cash burn, a worsening working capital deficit, and an explicit 'going concern' warning from management. While there's a strategic pivot, the financial foundation is highly unstable.

Positives

• The company has strategically pivoted its continuing operations to precision medicine in cancer treatment, leveraging acquired laboratory capabilities and intellectual property licenses from Theralink Technologies, Inc.
• Interest expense decreased to $11,466 in Q1 2025 from $40,473 in Q1 2024.
• Net cash provided by financing activities improved to $560,000 in Q1 2025, primarily from common stock issuance and promissory notes, compared to a net cash used of $1,724 in Q1 2024.

Negatives

• Net loss from continuing operations significantly increased to $2,200,182 in Q1 2025 from $448,899 in Q1 2024.
• The company reported a gross loss of $101,687 in Q1 2025, compared to no gross loss in Q1 2024, indicating that current revenues do not cover the cost of revenues.
• Operating expenses more than quintupled to $2,087,214 in Q1 2025, largely due to increased employee and professional fees.
• Cash balance plummeted to $30,880 as of March 31, 2025, from $504,189 at the end of 2024.
• The working capital deficit worsened to $(8.5) million, driven by a $1.1 million increase in accounts payable and a $0.5 million increase in notes payable.
• Accumulated deficit grew to $67.2 million as of March 31, 2025, from $64.98 million at December 31, 2024.
• Net cash used in operating activities increased five-fold to $1.03 million in Q1 2025, indicating a higher cash burn rate.
• The company's management has concluded that there is substantial doubt about its ability to continue as a going concern.
• Significant liabilities from discontinued operations remain at approximately $4.0 million, including a $2.7 million reserve for a Medicare audit overpayment.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to historical and expected operating losses and cash outflows.
• The company's ability to obtain additional financing for projected growth and operations is critical and uncertain.
• Challenges exist in attracting competent, skilled laboratory and sales personnel at acceptable prices to manage overhead.
• Ongoing legal proceedings related to alleged Medicare overpayments from discontinued operations, totaling approximately $4.3 million, pose a financial risk.
• Inflation has had a material impact on staffing and supply costs, and future inflation could adversely affect operating results and financial condition.
• Material weaknesses in internal control over financial reporting, including insufficient accounting resources and lack of segregation of duties, could lead to financial misstatements and impact stock price or listing compliance.

Future Outlook

Management anticipates needing to raise additional capital to fund future operations and acknowledges that the company's financial condition raises substantial doubt about its ability to continue as a going concern. The company is evaluating the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) on its financial statements and disclosures.

Management Comments

• Management concludes that there is substantial doubt about the company's ability to continue as a going concern twelve months from the issuance of these statements due to historically incurring and expecting to incur operating losses and cash outflows from operations.
• Management plans to raise additional capital through the issuance of financial instruments, including both debt and equity, to mitigate the conditions and events that raise substantial doubt.
• Management acknowledges the risks associated with not having dedicated accounting personnel and anticipates expanding accounting functions with dedicated staff and improving internal accounting procedures and separation of duties when additional capital resources allow.

Industry Context

The company's strategic shift to precision medicine in cancer treatment aligns with a growing trend in healthcare towards personalized diagnostics and targeted therapies. This sector is characterized by high research and development costs, significant capital requirements, and a long pathway to commercialization, often necessitating substantial external funding. The company's current financial distress and limited revenue generation highlight the challenges of establishing a foothold in this capital-intensive industry.

Corporate Governance

Legal Proceedings

• The company is subject to a third-party audit by Covent Bridge Group, a CMS contractor, recommending an overpayment of approximately $2.7 million for Progressive Health & Rehabilitation, Ltd. for claims from July 2017 to November 2020. Appeals have been denied, and the company filed a lawsuit in federal court on May 14, 2025.
• Covent Bridge Group also recommended an overpayment of approximately $0.5 million for Advantage Therapy in May 2022. A partially favorable reconsideration was received, and the company awaits a response from an Administrative Law Judge hearing conducted in February 2024.
• In November 2024, the company received notification of an estimated $1.1 million overpayment of CMS funds at its IMAC St. Louis patient center for the period February 26, 2020, through January 2, 2024.

Related Party Transactions

• During the three months ended March 31, 2025, the company issued promissory notes with an aggregate principal amount of approximately $0.1 million to a related party, for cash proceeds of approximately $0.1 million.
• Subsequent to March 31, 2025, the company issued promissory notes of $0.1 million to a related party as part of the Q2 2025 Notes issuance.

Stakeholder Impact

• Shareholders face significant dilution risk due to the increase in authorized common stock and ongoing capital raising efforts through equity and convertible debt.
• Shareholders are experiencing substantial value erosion due to the worsening net loss and accumulated deficit.
• Creditors face increased risk given the company's 'going concern' warning, high current liabilities, and reliance on future capital raises.
• Employees may face uncertainty regarding job security and compensation given the company's financial distress and plans to expand accounting functions only when additional capital is available.
• Vendors are impacted by the significant increase in accounts payable and accrued expenses, indicating potential payment delays or increased credit risk.

Next Steps

• Raise additional capital through debt and equity issuances to fund future operations and address going concern issues.
• Expand accounting functions with dedicated staff and improve internal accounting procedures and separation of duties when additional capital resources become available.
• Continue appeals processes for alleged Medicare overpayments, including the federal court lawsuit for Progressive Health and awaiting the ALJ response for Advantage Therapy.

Key Dates

Recommendation

Keywords

IMAC Holdings, Ignite Proteomics, precision medicine, cancer treatment, RPPA technology, SEC filing, 10-Q, financial results, net loss, going concern, capital raise, CMS audit, internal controls, liquidity, working capital deficit